You are writing an initiation note on a listed mid-cap specialty chemicals maker (a hypothetical company).
Write the opening of an equity research note: rating, 12-month target price and thesis first, then the valuation, the key drivers and the main risks. Show your valuation arithmetic.
100 points, 60% to pass.
Market cap = ₹1,240 × 10 crore = ₹12,400 crore; EV = ₹13,200 crore. FY26 EBITDA = ₹720 crore, so the stock trades at about 18.3x trailing. On guidance, FY27 revenue ₹4,600 crore at ~19% margin ≈ ₹874 crore EBITDA → at the 16x median, EV ≈ ₹13,980 crore, equity ≈ ₹13,180 crore, about ₹1,318 a share — only ~6% upside, and that assumes guidance is met. A delayed plant (history says likely) keeps margins nearer 18% and removes the upside. The strong answer notices that the stock already prices in guidance, weighs execution and customer-concentration risk, and so lands on hold or sell unless there is a reason to pay above the peer median — and states the falsifier: the plant commissioning on time.